Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from MetaVia ( (MTVA) ).
On November 7, 2025, MetaVia Inc. announced positive results from its Phase 2a clinical trial of vanoglipel (DA-1241), a GPR119 agonist, as a potential treatment for MASH. The trial demonstrated vanoglipel’s ability to improve glucose control, liver health, and plasma lipidomic profiles after 16 weeks of treatment, highlighting its potential to address both hepatic and metabolic components of MASH. The data, presented at the AASLD The Liver Meeting® 2025, showed significant reductions in HbA1c, liver inflammation, and fibrosis, reinforcing vanoglipel’s potential as a monotherapy and combination therapy for MASH and related metabolic disorders.
The most recent analyst rating on (MTVA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
Spark’s Take on MTVA Stock
According to Spark, TipRanks’ AI Analyst, MTVA is a Underperform.
MetaVia’s overall stock score is heavily impacted by its poor financial performance, characterized by persistent losses and no revenue generation. The technical analysis indicates weak market momentum, and negative valuation metrics highlight the stock’s high-risk profile. Although recent positive trial results provide some potential for future growth, significant strategic changes are necessary for the company to achieve financial stability and investor confidence.
To see Spark’s full report on MTVA stock, click here.
More about MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for obesity treatment and Vanoglipel (DA-1241) for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Average Trading Volume: 1,954,059
Technical Sentiment Signal: Sell
Current Market Cap: $24.2M
Learn more about MTVA stock on TipRanks’ Stock Analysis page.